Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X:
Abstract 94
ASCO GU 2026 by Gabriel Hooper. Rx patterns of ~5000 pts w/ mCRPC prostate cancer in Flatiron Health. ARPIs and taxanes remained most common 1L Rx only ~50% received 2L Rx suggesting need to optimize sequencing.
Title: Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated between 2021-2025
Authors: Gabriel Hooper, Yeonjung Jo, Georges Gebrael, Zeynep Irem Ozay, Varun Nandakumar, Ethan Murdock, Chadi Hage Chehade, Micah Ostrowski, Nicolas Sayegh, Patrick Campbell, Roberto H. Nussenzveig, Vinay Mathew Thomas, Neeraj Agarwal, Umang Swami
Read The Full Article
Abstract 546
ASCO GU 2026 by Alex Zhu. AI-derived digital pathology biomarker (CHAI) independently prognostic for progression and OS in localized RCC kidney cancer further validation needed.
Title: Development and validation of a computational histology artificial intelligence (CHAI) prognostic biomarker in renal cell carcinoma
Authors: Alex Zhu, Viswesh Krishna, Vrishab Krishna, Gaurav Kaul, Vivek Nimgaonkar, Snehal S. Sonawane, Lesli A. Kiedrowski, Trevor Royce, Anirudh Joshi, Sumanta K. Pal
Read The Full Article
Abstract 487
ASCO GU 2026 Congrats Paulo G Bergerot and team participation in remote exercise program was associated w/ QOL (decreased fatigue) in pts w/ metastatic GU cancers.
Title: Effect of remote exercise on fatigue and quality of life (QOL) across genitourinary (GU) cancer types
Authors: Paulo G. Bergerot, Cristiane D. Bergerot, Jonas R. Silva, Marcos V. Franca, William H. Fuzita, Murilo Buso, Alessandra Leite, Carlos Watanabe, Patricia W. Schorn, Narjust Florez, Sumanta K. Pal, Kathryn H. Schmitz
Read The Full Article
Abstract 528
ASCO GU 2026 by Yu-Wei Chen. PI3K/AKT/mTOR and DDR alterations were associated w/ response to belzutifan in RCC kidney cancer prospective validation needed.
Title: Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 240 RCC patients
Authors: Yu-Wei Chen, Shayan S. Nazari, Andrew Elliott, Ninad Kulkarni, Norm Smith, Rashad Nawfal, Liliana Ascione, Marc Machaalani, Pedro C. Barata, Brent S. Rose, Aditya Bagrodia, Neeraj Agarwal, Sumanta K. Pal, Toni K. Choueiri, Rana R. McKay
Read The Full Article
Abstract 507
ASCO GU 2026 by Ali Moradi. Long-term outcomes w/ live bacteria (CBM588) in mRCC kidney cancer addition of CBM588 to frontline ICI Rx ORR and PFS supporting upcoming Ph3 SWOG. BIOFRONT study.
Title: Long-term clinical outcomes with Clostridium butyricum MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC)
Authors: Ali Moradi, Nazli Dizman, Hedyeh Ebrahimi, Xinran Qi, Antonio Cruz Gomes, Miguel Zugman, Salvador Jaime-Casas, Vitor Abreu De Goes, Xiaochen Li, Tanya B. Dorff, Joann Hsu, Alexander Chehrazi-Raffle, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Peter P. Lee, Thomas P. Parks, Jennifer Karmouch, Robert Jeng, Sumanta K. Pal
Abstract 488
ASCO GU 2026 by Gabriel Hooper, pts w/ mRCC kidney cancer on belzutifan 53% had gr≥3 hypoxia, 80% gr≥2 anemia data suggest close monitoring of pts on belzutifan living/visiting high altitude areas.
Title: Incidence of symptomatic hypoxia in a high-altitude cohort of patients with renal cell carcinoma (RCC) treated with belzutifan
Authors: Taylor R. McFarland, Audrey Seidel, Georges Gebrael, Zeynep Irem Ozay, Gabriel Hooper, Micah Ostrowski, Richard Ji, Varun Nandakumar, Haoran Li, Benjamin L. Maughan, Umang Swami, Julia Batten, Neeraj Agarwal
Read The Full Article
Abstract 634
ASCO GU 2026 by Michiel van der Heijden, addition of anti-LAG3 or anti-TIGIT ICIs to EV+pembro in mUC did not improve efficacy of EV+P bladder cancer higher irAEs w/coformulations.
Title: KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC)
Authors: Michiel S. Van Der Heijden, Michal Sarfaty, Christian Caglevic, Marine Gross-Goupil, Eli Rosenbaum, Jae Lyun Lee, Thomas Powles, Srikala S. Sridhar, Carlos Rojas, Sang Joon Shin, Debbie G. Robbrecht, Javier Puente, Rafael Morales-Barrera, Wen-Pin Su, Yu-Li Su, Denis Maillet, April Wang, Abhishek A. Bavle, Blanca Homet Moreno, Avivit Peer
Read The Full Article
Abstract 686
ASCO GU 2026 Congrats Antonio Cigliola. Analysis of 2,383 pts w/mUC across 3 Rx eras bladder cancer OS improved from 13.5 mo(platinum-based Rx)-17.5 mo(ICI)-21.1 mo(ADC) greatest gains in the ADC era.
Title: Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras
Authors: Antonio Cigliola, Brigida Anna Maiorano, Valentina Tateo, Chiara Mercinelli, Michela Piacentini, Alessandro Bertini, Marco Mariani, Nazli Dizman, Sumanta K. Pal, Shilpa Gupta, Petros Grivas, Ashish M. Kamat, Philippe E. Spiess, Neeraj Agarwal, Alberto Briganti, Francesco Montorsi, Andrea Necchi
Read The Full Article
Abstract 446
ASCO GU 2026 by Martín Zarbá. Real-world outcomes w/1L Cabo+Nivo in mRCC kidney cancer ORR 41.6%, TTNT 19.4mo, OS 44.4mo, comparable to CM-9ER 2L TKIs active post-cabo, supporting this sequencing.
Title: Real-world efficacy of nivolumab plus cabozantinib in metastatic renal cell carcinoma (mRCC) using the IMDC
Authors: Martin Zarba, David Maj, Parker Baumgarten, J. C. Wells, Syed Irteza Abbas Shamsi, Martin Angel, Razane El Hajj Chehade, Rashad Nawfal, Lisa Ludwig, Chiming Yang, Federico Losco, Aurelius G. Omlin, Benoit Beuselinck, Sumanta K. Pal, Kosuke Takemura, Zeynep Irem Ozay, Ulka N. Vaishampayan, Winson Y. Cheung, Toni K. Choueiri, Daniel Y. Heng
Read The Full Article
Abstract 749
ASCO GU 2026 by Jean Hoffman-Censits, Petros Grivas, ECOG-ACRIN Cancer Research Group. Neoad Gem-Durva in cisplatin-unfit pts w/high grade UTUC bladder cancer pCR 10%, <ypT2N0/X 33%, promising 1-year EFS rate, manageable tox Ph3 ongoing in cisplatin-fit pts.
Title: ECOG ACRIN EA8192 cohort C: A phase II trial of neoadjuvant gemcitabine/durvalumab in patients (pts) with high grade (HG) upper tract urothelial carcinoma (UTUC) ineligible for cisplatin-based chemotherapy
Authors: Jeannie Hoffman-Censits, Xiangying Chu, Vitaly Margulis, Daniel Shevrin, Suzanne Cole, Ruben Raychaudhuri, Kriti Mittal, Sarah P. Psutka, Abhishek Tripathi, Noah M. Hahn, Michael A. Carducci, Petros Grivas
Read The Full Article
Abstract 692
ASCO GU 2026 by Zeynep Irem Ozay. Real-world analysis of 745 pts w/ aUC bladder cancer treated w/EV+Pembro Median OS 17 mo (low compared to ph3 trial) Data suggest need for improved management in RW pts.
Title: Real-world use and effectiveness of first-line enfortumab vedotin (EV) with pembrolizumab (P) in patients with advanced urothelial carcinoma (aUC)
Authors: Zeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, Varun Nandakumar, Richard T. Hardy, Chadi Hage Chehade, Ethan Murdock, Nicolas Sayegh, Roberto H. Nussenzveig, Vinay Mathew Thomas, Sumati Gupta, Haoran Li, Benjamin L. Maughan, Umang Swami, Neeraj Agarwal
Read The Full Article
Abstract 231
ASCO GU 2026. AI-powered digital histology (CHAI) biomarker (BM) in mHSPC prostate cancer using CHAARTED and ENZAMET BM+ status prognostic for PFS/OS and predicts benefit w/adding docetaxel or ARPI.
Title: Development and validation of computational histology artificial intelligence (CHAI)–powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET and CHAARTED prospective randomized phase 3 trials (RCT)
Authors: Neeraj Agarwal, Georges Gebrael, Umang Swami, Viswesh Krishna, Vrishab Krishna, Akshay Neema, Asit Tarsode, Vinod Subhash, Deepika Sirohi, Hala Borno, Drew Watson, Snehal S. Sonawane, Waleed Abuzeid, Vivek Nimgaonkar, Lesli A. Kiedrowski, Trevor Royce, Anirudh Joshi, Ian D. Davis, Christopher Sweeney
Read The Full Article
Abstract 687
ASCO GU 2026 Congrats Diya Garg, GU Cancer Research Program. Merit Award Conquer Cancer. End-of-life Rx data in 7,815 pts w/aUC bladder cancer 67% remained on Rx 3 mo before death pts need better EOL care.
Title: End-of-life treatment patterns in patients with advanced urothelial carcinoma
Authors: Diya Garg, Yeonjung Jo, Georges Gebrael, Zeynep Irem Ozay, Varun Nandakumar, Nicolas Sayegh, Edwin Lin, Micah Ostrowski, Roberto H. Nussenzveig, Ayana Srivastava, Vinay Mathew Thomas, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami
Read The Full Article
Abstract 15
ASCO GU 2026 by Enrique Gallardo. Final OS from PEACE-3 in mCRPC prostate cancer Enza + Ra-223 vs Enza showed OS benefit (consistent across subgroups), no new safety signals.
Title: Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer
Authors: Enrique Gallardo, Bertrand F. Tombal, Ananya Choudhury, Fred Saad, Andrey Soares, Yohann Loriot, Raymond S. McDermott, Alejo Rodriguez-Vida, Pedro Isaacsson Velho, Felipe J. Cruz, Thierry A. Roumeguere, Gedske Daugaard, Rosely Yamamura, Frederic Lecouvet, Corneel Coens, Coralie Poncet, Beatrice Fournier, Silke Gillessen
Read The Full Article
Other articles about ASCO on OncoDaily.
